Commonwealth Equity Services
SRPT icon

Commonwealth Equity Services’s Sarepta Therapeutics SRPT Stock Holding History

Commonwealth Equity Services’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,055
Closed -$514K – 4348
2025
Q1 		$514K Buy
8,055
+1,698
+27% +$179K ﹤0.01% 2999
2024
Q4 		$773K Buy
6,357
+1,151
+22% +$141K ﹤0.01% 2607
2024
Q3 		$650K Sell
5,206
-82
-2% -$11.3K ﹤0.01% 2685
2024
Q2 		$836K Buy
5,288
+45
+0.9% +$5.78K ﹤0.01% 2417
2024
Q1 		$679K Buy
5,243
+418
+9% +$51.2K ﹤0.01% 2554
2023
Q4 		$465K Buy
4,825
+415
+9% +$39.8K ﹤0.01% 2780
2023
Q3 		$535K Sell
4,410
-16
-0.4% -$1.81K ﹤0.01% 2539
2023
Q2 		$507K Sell
4,426
-410
-8% -$52.9K ﹤0.01% 2615
2023
Q1 		$666 Sell
4,836
-25
-0.5% -$3.24K ﹤0.01% 2315
2022
Q4 		$629K Buy
4,861
+248
+5% +$28.7K ﹤0.01% 2288
2022
Q3 		$509K Buy
4,613
+7
+0.2% +$706 ﹤0.01% 2391
2022
Q2 		$345K Sell
4,606
-3
-0.1% -$221 ﹤0.01% 2713
2022
Q1 		$360K Sell
4,609
-53
-1% -$4.06K ﹤0.01% 2804
2021
Q4 		$419K Sell
4,662
-101
-2% -$8.63K ﹤0.01% 2681
2021
Q3 		$440K Buy
4,763
+392
+9% +$30.2K ﹤0.01% 2572
2021
Q2 		$339K Sell
4,371
-200
-4% -$15.2K ﹤0.01% 2792
2021
Q1 		$340K Sell
4,571
-4,184
-48% -$386K ﹤0.01% 2661
2020
Q4 		$1.49M Sell
8,755
-251
-3% -$37.2K ﹤0.01% 1400
2020
Q3 		$1.26M Buy
9,006
+491
+6% +$74.6K ﹤0.01% 1357
2020
Q2 		$1.36M Buy
8,515
+391
+5% +$53.2K 0.01% 1239
2020
Q1 		$794K Sell
8,124
-3,096
-28% -$354K ﹤0.01% 1391
2019
Q4 		$1.45M Buy
11,220
+269
+2% +$27.2K 0.01% 1211
2019
Q3 		$824K Buy
10,951
+1,497
+16% +$177K ﹤0.01% 1478
2019
Q2 		$1.44M Buy
9,454
+290
+3% +$35.2K 0.01% 1134
2019
Q1 		$1.09M Buy
9,164
+158
+2% +$20.3K 0.01% 1256
2018
Q4 		$982K Sell
9,006
-217
-2% -$27.1K 0.01% 1212
2018
Q3 		$1.49M Buy
9,223
+234
+3% +$32K 0.01% 1082
2018
Q2 		$1.19M Buy
8,989
+892
+11% +$84.1K 0.01% 1189
2018
Q1 		$599K Sell
8,097
-994
-11% -$66.3K ﹤0.01% 1590
2017
Q4 		$506K Buy
9,091
+1,377
+18% +$72.9K ﹤0.01% 1693
2017
Q3 		$350K Buy
7,714
+650
+9% +$26K ﹤0.01% 1858
2017
Q2 		$238K Buy
+7,064
New +$230K ﹤0.01% 2091
2016
Q3 		– Sell
-15,828
Closed -$302K – 2302
2016
Q2 		$302K Buy
+15,828
New +$293K ﹤0.01% 1654
2016
Q1 		– Sell
-5,430
Closed -$209K – 2261
2015
Q4 		$209K Buy
+5,430
New +$176K ﹤0.01% 1846
2014
Q3 		– Sell
-10,428
Closed -$311K – 2136
2014
Q2 		$311K Buy
10,428
+425
+4% +$13.4K ﹤0.01% 1521
2014
Q1 		$240K Buy
+10,003
New +$255K ﹤0.01% 1630

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Commonwealth Equity Services's SRPT Position: Q2 2025 in Review

Commonwealth Equity Services sold out of Sarepta Therapeutics (SRPT) in Q2 2025, closing a stake of 8,055 shares — an estimated $514K sold.

Commonwealth Equity Services first reported a position in SRPT in Q1 2014 and held it in 36 quarters. The position peaked at $1.49M in Q4 2020. 362 funds tracked by Wall St. Rank hold SRPT as of Q2 2025.

  • Commonwealth Equity Services reported no remaining Sarepta Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Commonwealth Equity Services sold 8,055 Sarepta Therapeutics shares in Q2 2025, an estimated $514K.
  • Commonwealth Equity Services first reported a position in Sarepta Therapeutics in Q1 2014 and held it in 36 quarters.
  • Commonwealth Equity Services's Sarepta Therapeutics position peaked at $1.49M in Q4 2020.
  • 362 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2025.

Based on Commonwealth Equity Services's 13F filing for Q2 2025, filed 6 Aug 2025.